Contrast enhanced-magnetic resonance imaging as a surrogate to map verteporfin delivery in photodynamic therapy
- PMID: 24365954
- PMCID: PMC3870269
- DOI: 10.1117/1.JBO.18.12.120504
Contrast enhanced-magnetic resonance imaging as a surrogate to map verteporfin delivery in photodynamic therapy
Abstract
The use of in vivo contrast-enhanced magnetic resonance (MR) imaging as a surrogate for photosensitizer (verteporfin) dosimetry in photodynamic therapy of pancreas cancer is demonstrated by correlating MR contrast uptake to ex vivo fluorescence images on excised tissue. An orthotopic pancreatic xenograft mouse model was used for the study. A strong correlation (r = 0.57) was found for bulk intensity measurements of T1-weighted gadolinium enhancement and verteporfin fluorescence in the tumor region of interest. The use of contrast-enhanced MR imaging shows promise as a method for treatment planning and photosensitizer dosimetry in human photodynamic therapy (PDT) of pancreas cancer.
Figures



References
-
- Huggett M. T., et al. , “Photodynamic therapy of locally advanced pancreatic cancer (VERTPAC study): final clinical results,” Proc. SPIE 8568, 85680J (2013).PSISDG10.1117/12.2013648 - DOI
-
- Sandanayake N. S., et al. , “Photodynamic therapy for locally advanced pancreatic cancer: early clinical results,” Proc. SPIE 7551, 75510L (2010).PSISDG10.1117/12.846555 - DOI
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical